Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Meningococcemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4 result(s) found for: Meningococcemia. Displaying page 1 of 1.
    EudraCT Number: 2014-003504-79 Sponsor Protocol Number: V59P13 Start Date*: 2014-10-24
    Sponsor Name:Novartis Vaccines & Diagnostics, Inc.
    Full Title: A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Investigational Meningococcal ACWY Conjugate Vaccine when One Dose is Administered t...
    Medical condition: Novartis Meningococcal ACWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, C, W and Y.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10027280 Meningococcal sepsis PT
    17.1 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    17.1 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    17.1 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    17.1 10021881 - Infections and infestations 10040081 Septicaemia meningococcal LLT
    17.1 10021881 - Infections and infestations 10040048 Sepsis meningococcal LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004609-42 Sponsor Protocol Number: OVG2017/08 Start Date*: 2018-02-21
    Sponsor Name:Clinical Trials and Research Governance (CTRG), University of Oxford
    Full Title: Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage
    Medical condition: Oropharyngeal meningococcal carriage. Meningococci have the potential to cause invasive meningococcal disease. This study investigates the ability of Meningococcal B vaccines to reduce the carriage...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    20.0 10021881 - Infections and infestations 10027268 Meningococcaemia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001549-15 Sponsor Protocol Number: C0921004 Start Date*: 2013-09-19
    Sponsor Name:Pfizer Inc (235 East 42nd Street, New York, New York 10017)
    Full Title: The long-term antibody persistence of MenACWY-TT vaccine (PF-06866681) versus Meningitec® or Mencevax® ACWY in healthy adolescents and adults and a booster dose of MenACWY-TT administered 10 years ...
    Medical condition: Meningococcal disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.1 100000004862 10028912 Neisseria meningitis sepsis LLT
    18.1 100000004862 10027276 Meningococcal meningitis LLT
    18.1 100000004862 10058885 Meningococcal bacteremia LLT
    18.1 100000004862 10027275 Meningococcal infection, unspecified LLT
    18.1 100000004862 10040048 Sepsis meningococcal LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-002251-42 Sponsor Protocol Number: 3-001 Start Date*: 2012-11-05
    Sponsor Name: Asahi Kasei Pharma America Corporation
    Full Title: A RANDOMIZED, DOUBLE BLIND, PLACEBO–CONTROLLED, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART-123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY
    Medical condition: severe sepsis and coagulopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) HU (Completed) FI (Completed) CZ (Completed) ES (Completed) BG (Prematurely Ended) GB (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Nov 09 08:14:37 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA